64 results about "Lisinopril" patented technology

A stable pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutical acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril and combinations thereof; wherein the formation of an internal cyclization product, and / or ester hydrolysis product, and / or oxidation product, has been reduced or eliminated, and the weight percents are based on the total weight of the pharmaceutical composition. The stabilized pharmaceutical compositions of the invention exhibit a number of advantages as follows: (i) the ACE inhibitor or a pharmaceutical acceptable salt thereof present in the compositions is preserved from degradation; (ii) the compositions exhibit extended shelf-life under normal storage conditions; (iii) the effect of moisture on the compositions is minimized; (iv) the compositions exhibit minimal, if any, discoloration over a significant period of time; and (v) the compositions exhibit minimal, if any, instability when employed in the presence of colorants.

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

The invention relates to a lisinopril-containing compound preparation for treating hypertension, which comprises the main components of L-amlodipine or pharmaceutically acceptable salt thereof, hydrochlorothiazide and lisinopril or pharmaceutically acceptable salt thereof, and the auxiliary component of a pharmaceutically acceptable carrier, wherein the content of the L-amlodipine or the pharmaceutically acceptable salt thereof in unit preparation is 2.5-10.0mg. The invention has the advantages of fully exerting medicine compensation action mechanism through medicine combination therapy, increasing curative effect, quickly reaching the standards, making the compliance rate of blood pressure reach 82%, reducing adverse effect associated with the dose increase of certain medicine and keeping longer action time. The compound preparation has the characteristics of quick effect taking, high compliance rate of blood pressure, little side effect and low cost.

A method for preparing a lisinopril intermediate is provided. The method includes: treating (R)-hydroxy-4-phenylbutyrate with sulfonyl chloride in an organic solvent in the presence of a base to obtain a solution of sulfonate; reacting the obtained solution with a salt of trifluoroacetyl lysine; and obtaining a N2-[1-(S)-alkoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyl-L-lysine by separating after the reaction is completed. The method provided has a shorter synthesis route, is easy to operate, has a low cost, and is suitable for industrial production.

Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

The invention provides a method for preparing a lisinopril intermediate. The lisinopril intermediate is (R)-2-hydroxyl-4-phenylbutyrate. The method has the advantages that the lisinopril intermediate is made of inexpensive and easily available raw materials which are benzaldehyde and pyruvic acid, four-step efficient reaction including condensation, biological enzyme catalytic asymmetric reduction, double-bond hydrogenation and esterification is carried out on the benzaldehyde and the pyruvic acid, and accordingly an optically pure target product (R)-HPBE [(R)-2-hydroxyl-4-phenylbutyrate] can be ultimately obtained at the overall yield of 83%.